Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 9/20 | 0.42 |
| ▸ | CTSS | P25774 | 7/20 | 0.42 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4811672 | 0.96 | MEN1 (0.50) | MEN1GAAKMT2ATDP1CTSK | |
| SCHEMBL7730493 | 0.91 | MEN1 (0.62) | MEN1GAAKMT2ATDP1CTSK | |
| SCHEMBL19301024 | 0.91 | MEN1 (0.62) | MEN1GAAKMT2ATDP1CTSK | |
| SCHEMBL12666362 | 0.91 | MEN1 (0.62) | MEN1GAAKMT2ATDP1CTSK | |
| SCHEMBL5182483 | 0.91 | MEN1 (0.46) | MEN1GAAKMT2ATDP1CTSK | |
| SCHEMBL3185091 | 0.88 | MEN1 (0.63) | MEN1GAAKMT2ATDP1CTSK | |
| SCHEMBL3176198 | 0.87 | MEN1 (0.54) | MEN1GAAKMT2ATDP1CTSK | |
| SCHEMBL23168272 | 0.87 | TDP1 (0.59) | MEN1GAAKMT2ATDP1CTSK | |
| SCHEMBL8062203 | 0.87 | TDP1 (0.59) | MEN1GAAKMT2ATDP1CTSK | |
| SCHEMBL10190369 | 0.87 | TDP1 (0.59) | MEN1GAAKMT2ATDP1CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070142638-A1 | Ornithine derivatives as prostaglandin e2 agonists or antagonists | ASTELLAS PHARMA INC. (JP) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142638-A1 | Ornithine derivatives as prostaglandin e2 agonists or antagonists | PTGER4, OXER1, RXFP4 | MEN1 4001/4885GAA 4769/4885KMT2A 1128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.